Trial · NCT02546375
Outcomes19
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With Cumulative Complete Haematological Response (CHR) | Baseline up to 5.5 years | All enrolled participants with Philadephia chromosome positive CML in chronic phase received at least 1 dose of Bosutinib. Here, number of participants analyzed (N) signifies those participants who were evaluable for this outcome measure. | percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With Cumulative Partial Haematological Response (PHR) | Baseline up to 5.5 years | All enrolled participants with Philadephia chromosome positive CML in chronic phase received at least 1 dose of Bosutinib. Here, N signifies those participants who were evaluable for this outcome measure. | percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With Cumulative Complete Cytogenetic Response (CCyR) | Baseline up to 5.5 years | All enrolled participants with Philadephia chromosome positive CML in chronic phase received at least 1 dose of Bosutinib. Here, N signifies those participants who were evaluable for this outcome measure. | percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With Cumulative Minor Cytogenetic Response (MCyR) | Baseline up to 5.5 years | All enrolled participants with Philadephia chromosome positive CML in chronic phase received at least 1 dose of Bosutinib. Here, N signifies those participants who were evaluable for this outcome measure. | percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With Cumulative Minimal Cytogenetic Response (mCyR) | Baseline up to 5.5 years | All enrolled participants with Philadephia chromosome positive CML in chronic phase received at least 1 dose of Bosutinib. Here, N signifies those participants who were evaluable for this outcome measure. | percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With Cumulative Partial Cytogenetic Response (PCyR) | Baseline up to 5.5 years | All enrolled participants with Philadephia chromosome positive CML in chronic phase received at least 1 dose of Bosutinib. Here, N signifies those participants who were evaluable for this outcome measure. | percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With Cumulative Complete Molecular Response 4.0 (MR4.0) | Baseline up to 5.5 years | All enrolled participants with Philadephia chromosome positive CML in chronic phase received at least 1 dose of Bosutinib. Here, N signifies those participants who were evaluable for this outcome measure. | percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With Cumulative Complete Molecular Response 4.5 (MR4.5) | Baseline up to 5.5 years | All enrolled participants with Philadephia chromosome positive CML in chronic phase received at least 1 dose of Bosutinib. Here, N signifies those participants who were evaluable for this outcome measure. | percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With Cumulative Major Molecular Response (MMR)/Molecular Response 3.0 (MR3.0) | Baseline up to 5.5 years | All enrolled participants with Philadephia chromosome positive CML in chronic phase received at least 1 dose of Bosutinib. Here, N signifies those participants who were evaluable for this outcome measure. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Treatment Related Adverse Events (AEs) | Baseline up to 5.5 years | All enrolled participants with Philadephia chromosome positive CML in chronic phase received at least 1 dose of Bosutinib. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Treatment Related Adverse Events (AEs) Greater Than or Equal to Grade 3 | Baseline up to 5.5 years | All enrolled participants with Philadephia chromosome positive CML in chronic phase received at least 1 dose of Bosutinib. | percentage of participants | NUMBER |
| SECONDARY | Progression-free Survival (PFS) | Year 1, 2, 3 | All enrolled participants with Philadephia chromosome positive CML in chronic phase received at least 1 dose of Bosutinib. | years | MEDIAN |
| SECONDARY | Overall Survival (OS) | From baseline up to 1 Year, baseline up to Year 2, baseline up to Year 3 | All enrolled participants with Philadephia chromosome positive CML in chronic phase received at least 1 dose of Bosutinib. | years | MEDIAN |
| SECONDARY | Percentage of Participants With Disease Progression | Year 1, 2, 3 | All enrolled participants with Philadephia chromosome positive CML in chronic phase received at least 1 dose of Bosutinib. Here, N signifies those participants who were evaluable for this outcome measure and number analyzed (n) signifies those participants who were evaluable at specified time points only. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Permanent Discontinuation From Bosutinib Therapy | Baseline up to 5.5 years | All enrolled participants with Philadephia chromosome positive CML in chronic phase received at least 1 dose of Bosutinib. | percentage of participants | NUMBER |
| SECONDARY | Cross-Intolerance Between Bosutinib and Previous Therapy | Baseline up to 5.5 years | All enrolled participants with Philadephia chromosome positive CML in chronic phase received at least 1 dose of Bosutinib. | percentage of participants | NUMBER |
| SECONDARY | Mean Dose of Bosutinib at Initiation of Treatment | Baseline up to 5.5 years | All enrolled participants with Philadephia chromosome positive CML in chronic phase received at least 1 dose of Bosutinib. | milligram per day | MEAN |
| SECONDARY | Relative Bosutinib Dose Intensity | Baseline up to 5.5 years | All enrolled participants with Philadephia chromosome positive CML in chronic phase received at least 1 dose of Bosutinib. | percentage of daily dose | NUMBER |
| SECONDARY | Duration of Bosutinib Therapy | Baseline up to 5.5 years | All enrolled participants with Philadephia chromosome positive CML in chronic phase received at least 1 dose of Bosutinib. | months | MEDIAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02546375/outcomes